Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
Sponsored By: Representative Hoyle, Val T. [D-OR-4]
Introduced
Summary
reasonable pricing obligation would require that biomedical products and services developed with federal research support meet price limits set by HHS. The bill ties U.S. prices to a reference median price from Canada and six other high‑income OECD countries, adds mandatory public reporting, and creates a waiver and regulatory toolkit for enforcing or adjusting prices.
Show full summary
- Families and patients: Would cap prices for taxpayer‑supported drugs, vaccines, devices, diagnostics, and gene or cell therapies to a reference median from Canada and six other high‑income countries to help lower costs and improve access.
- Manufacturers and licensees: Would force pricing terms into funding and licensing agreements and require public reporting of each clinical trial's costs, any federal subsidies for those trials, and annual revenues by county.
- Federal agencies and HHS: Would give the Secretary of Health and Human Services authority to define “reasonable price,” issue regulations that can lower prices or shorten exclusivity when revenues exceed targets, and grant public, commentable waivers when warranted.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Price limits for taxpayer-funded drugs
This bill would require federal research contracts and related licenses for biomedical products to include a clause that prices be reasonable, as set by HHS. It would generally limit U.S. prices so they do not exceed the median price in Canada and six other reference countries, unless the HHS Secretary grants a public-interest waiver after notice, comment, and an economic analysis. The Secretary would be able to issue rules to enforce price reasonableness, including lowering prices or shortening exclusivity when revenues exceed targets or prices create access or fiscal burdens. Manufacturers would have to report each clinical trial's costs that supported approval, any federal subsidies of those costs, and annual product revenues by county; those reports would be public. The bill also defines covered products and how the six reference countries are chosen.
Sponsors & CoSponsors
Sponsor
Hoyle, Val T. [D-OR-4]
OR • D
Cosponsors
Rep. Doggett, Lloyd [D-TX-37]
TX • D
Sponsored 8/13/2026
Rep. Stansbury, Melanie A. [D-NM-1]
NM • D
Sponsored 8/13/2026
Rep. Takano, Mark [D-CA-39]
CA • D
Sponsored 8/13/2026
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 8/13/2026
Rep. Tlaib, Rashida [D-MI-12]
MI • D
Sponsored 8/13/2026
Rep. Jayapal, Pramila [D-WA-7]
WA • D
Sponsored 8/13/2026
Rep. Casar, Greg [D-TX-35]
TX • D
Sponsored 8/13/2026
Rep. Tokuda, Jill N. [D-HI-2]
HI • D
Sponsored 8/20/2026
Rep. Cohen, Steve [D-TN-9]
TN • D
Sponsored 8/20/2026
Rep. Khanna, Ro [D-CA-17]
CA • D
Sponsored 8/20/2026
Rep. García, Jesús G. "Chuy" [D-IL-4]
IL • D
Sponsored 8/20/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov